# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Oral Dose of TAK-418 in Healthy Female Participants

> **NCT03501069** · PHASE1 · TERMINATED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 32 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** TAK-418
- **DRUG:** TAK-418 Matching Placebo

## Key facts

- **NCT ID:** NCT03501069
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-05-30
- **Primary completion:** 2018-12-26
- **Final completion:** 2018-12-26
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** Business Decision; no human safety concern; evaluating preclinical toxicology finding
- **Last updated:** 2020-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03501069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03501069, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Oral Dose of TAK-418 in Healthy Female Participants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03501069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*